Advanced Colorectal Cancer Clinical Trial
Official title:
A Multi-cohort and Controlled Study to Evaluate the Efficacy and Safety of Surufatinib Combined With Chemotherapy as Second-line Treatment of Metastatic Colorectal Cancer
A phase II, muti-cohort study to assess the efficacy and safety of Surufatinib combined with chemotherapy as a second-line treatment in patients with advanced CRC
This study adopt Simon's two-stage minimax designs method based on the primary endpoint of objective response rates. In each arm, 15 patients were planned for the first stage. If two or more responses were observed, an additional 13 patients were to be accrued for a total of 28 patients. If 7 or more of the 28 patients in an arm achieved an objective response, then that arm was designated worthy of additional investigation. Surufatinib will be orally administered within 1 hour after breakfast once a day (QD) , Cohort 1 :Surufatinib+mFOLFOX6/FOLFIRI,Cohort 2 :Surufatinib+FOLFOXIRI for every 14-day treatment cycle until disease progression, death, intolerable toxicity or other protocol specified end-of-treatment criteria is met (which comes first). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
| Recruiting |
NCT06200363 -
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT02923622 -
Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer
|
N/A | |
| Completed |
NCT01723969 -
Screening Platform for Clinical Trials in Advanced Colorectal Cancer
|
||
| Active, not recruiting |
NCT00309179 -
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03699111 -
Identification of New Patient Stratification Tools in MSS RAS mt mCRC
|
||
| Not yet recruiting |
NCT02826837 -
LEAC-102 for Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05077839 -
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC
|
Phase 2 | |
| Recruiting |
NCT04324476 -
A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06369259 -
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00707889 -
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT01271166 -
Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT00386828 -
Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial
|
Phase 2 | |
| Recruiting |
NCT04764006 -
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
|
Phase 2 | |
| Active, not recruiting |
NCT04835324 -
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
|
||
| Active, not recruiting |
NCT02619435 -
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT01822444 -
ANGIOPREDICT. ICORG 12-16, V3
|
||
| Completed |
NCT00498407 -
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05731336 -
A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
|
||
| Active, not recruiting |
NCT04744831 -
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
|
Phase 2 |